Clinical Trial

A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain

Recruiting Early Phase 1

Summary

Previous studies have shown that the anterior cingulate cortex is involved in the regulation of pain and its associated negative emotions, that pyramidal neurons are highly excitable in chronic neuropathic pain conditions, and that silencing of pyramidal neurons can eliminate pain. The aim of this study was to evaluate the safety, tolerability, and efficacy of intracranial injection of GA (containing the hM4Di gene) in the anterior cingulate cortex in combination with oral clozapine for the treatment of refractory neuropathic pain.

Protocol Amendment History 2 changes

notable Primary completion pushed: 2026-03-31 -> 2026-12-31 2026-08-01

minor Completion pushed: 2026-06-30 -> 2026-12-31 2026-08-01

Trial Details

NCT Number	NCT06596681
Lead Sponsor	Beijing Tiantan Hospital
Conditions	Pain, Intractable
Enrollment	6 participants
Start Date	2024-09-11
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-31